Mr. Aloi is a pharmaceutical executive and entrepreneur with over thirty years’ experience in the epinephrine and respiratory products marketplace. He founded and served as CEO of Aero Pharmaceuticals, a specialty pharmaceuticals provider serving the asthma and allergy market. Mr. Aloi spent 18 years with Center Laboratories (a division of E. Merck), where he co-led the market launch of the EpiPen epinephrine autoinjector. As Director of Sales and Marketing, he managed the national sales force and marketing staff for EpiPen and other Center products. Mr. Aloi has served in leadership and advisory roles for the Allergen Product Manufacturers Association, the American College of Allergy & Immunology and the Joint Council of Allergy Asthma & Immunology. He is a graduate of Boston College.
Ms. Goodman is the CEO of FourCe, a provider of consulting services for regulatory filing and quality control for new pharmaceutical development. Formerly, she was Head Global Drug Safety and PV for Novartis. Earlier, she was responsible for drug safety management at Bausch & Lomb and served as a safety officer for Quintiles. Ms. Goodman began her career in healthcare as a pediatric heart/lung transplant nurse. She is Chairman of Eureka! Biosciences, a non-profit foundation that fosters the development and production of new drugs, devices, therapies to treat or cure diseases that affect children and families. She is a graduate of George Mason University.